Mirae Asset Global Investments Co. Ltd. Reduces Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Mirae Asset Global Investments Co. Ltd. decreased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 2.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,174 shares of the biopharmaceutical company’s stock after selling 1,702 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Catalyst Pharmaceuticals were worth $961,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sherbrooke Park Advisers LLC purchased a new position in shares of Catalyst Pharmaceuticals in the third quarter worth about $123,000. PNC Financial Services Group Inc. lifted its stake in Catalyst Pharmaceuticals by 42.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 11,241 shares of the biopharmaceutical company’s stock valued at $131,000 after acquiring an additional 3,354 shares during the period. CenterBook Partners LP boosted its holdings in shares of Catalyst Pharmaceuticals by 20.0% in the 3rd quarter. CenterBook Partners LP now owns 13,577 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 2,259 shares during the last quarter. Gallacher Capital Management LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the third quarter worth $206,000. Finally, DekaBank Deutsche Girozentrale purchased a new position in shares of Catalyst Pharmaceuticals during the third quarter worth $236,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on CPRX. Citigroup started coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 14th. They set a “buy” rating and a $27.00 price target on the stock. TheStreet raised Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a report on Tuesday, March 12th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 21st. Cantor Fitzgerald restated an “overweight” rating and issued a $34.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, March 22nd. Finally, Bank of America began coverage on Catalyst Pharmaceuticals in a report on Thursday, March 7th. They issued a “buy” rating and a $23.00 price target for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $26.43.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, Director David S. Tierney sold 25,000 shares of the company’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $15.68, for a total transaction of $392,000.00. Following the completion of the sale, the director now owns 348,874 shares of the company’s stock, valued at $5,470,344.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 12.10% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Stock Down 2.5 %

CPRX opened at $14.73 on Wednesday. Catalyst Pharmaceuticals, Inc. has a twelve month low of $11.09 and a twelve month high of $17.76. The company has a market cap of $1.74 billion, a PE ratio of 24.25, a price-to-earnings-growth ratio of 0.83 and a beta of 0.89. The company has a 50-day moving average price of $15.44 and a 200 day moving average price of $14.59.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.04. The business had revenue of $110.57 million during the quarter, compared to analysts’ expectations of $105.78 million. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. As a group, sell-side analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.81 earnings per share for the current year.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.